Next Article in Journal
Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients
Previous Article in Journal
The relationship between abuse, psychosocial factors, and pain complaints among older persons in Europe
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessOther

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians

1
Institute of Oncology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
2
Radiotherapy and Drug Therapy Centre, National Cancer Institute, Vilnius University, Vilnius, Lithuania
3
Department of Oncology, Klaipėda University Hospital, Klaipėda, Lithuania
4
Department of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
5
Clinic of Internal Diseases, Family Medicine, Gerontology and Oncology, Vilnius University, Vilnius, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2014, 50(4), 197-203; https://doi.org/10.1016/j.medici.2014.09.004
Received: 25 October 2013 / Accepted: 15 September 2014 / Published: 1 October 2014
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone health in cancer care. Patients with breast cancer treated or intended to be treated with aromatase inhibitors belong to a high-risk group becausetheir fracture risk increases up to 30% due to a significant decrease in bone mineral density within 6–12 months after the start of hormonal treatment. To evaluate bone status and predict risk for fractures, lateral thoracic and lumbar spine X-ray imaging, bone mineral density measurement by dual energy X-ray absorptiometry at the lumbar spine L1–L4 vertebrae and/or hip and fracture risk factors assessment are mandatory tests prior to hormonal treatment. Morbidity and mortality associated with bone loss can be prevented with appropriate screening, lifestyle interventions, and therapy. Algorithm for the management of bone health in breast cancer patients was established in Lithuania to screen patients with increased risk for bone loss and to provide adequate specific osteoporosis treatment.
Keywords: Aromatase inhibitors; Bone mineral density; Osteoporotic fracture; Specific osteoporosis treatment; Breast cancer Aromatase inhibitors; Bone mineral density; Osteoporotic fracture; Specific osteoporosis treatment; Breast cancer
MDPI and ACS Style

Juozaitytė, E.; Aleknavičius, E.; Jančiauskienė, R.; Česas, A.; Pipirienė-Želvienė, T.; Liutkauskienė, S.; Krasauskienė, A.; Vencevičienė, L. Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians. Medicina 2014, 50, 197-203.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop